Comparative effectiveness of the biosimilar CT-P13.

about

Comparative effectiveness of the biosimilar CT-P13.

Item

http://www.wikidata.org/entity/Q47418286

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Comparative effectiveness of the biosimilar CT-P13.

@en

Comparative effectiveness of the biosimilar CT-P13.

@nl

type

Item

label

Comparative effectiveness of the biosimilar CT-P13.

@en

Comparative effectiveness of the biosimilar CT-P13.

@nl

prefLabel

Comparative effectiveness of the biosimilar CT-P13.

@en

Comparative effectiveness of the biosimilar CT-P13.

@nl

P1476

Comparative effectiveness of the biosimilar CT-P13.

@en

P2093

Dae Hyun Yoo

http://www.w3.org/2001/XMLSchema#string

P2860

Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health

Assessing the Immunogenicity of Biopharmaceuticals

Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases

Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.

Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.

Physicochemical characterization of Remsima.

Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study

P304

693-712

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/CER-2017-0033

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29172717

http://www.w3.org/2001/XMLSchema#string